These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 22987850)

  • 21. Direct and indirect modulation of the N-methyl D-aspartate receptor.
    Marino MJ; Conn PJ
    Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):1-16. PubMed ID: 12769631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
    Jentsch JD; Roth RH
    Neuropsychopharmacology; 1999 Mar; 20(3):201-25. PubMed ID: 10063482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
    Large CH
    J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implications of PCP, NMDA and opiate receptors.
    Wilkins J
    NIDA Res Monogr; 1989; 95():275-81. PubMed ID: 2577034
    [No Abstract]   [Full Text] [Related]  

  • 27. Is the acute NMDA receptor hypofunction a valid model of schizophrenia?
    Adell A; Jiménez-Sánchez L; López-Gil X; Romón T
    Schizophr Bull; 2012 Jan; 38(1):9-14. PubMed ID: 21965469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.
    Paz RD; Tardito S; Atzori M; Tseng KY
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):773-86. PubMed ID: 18650071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.
    Coyle JT; Tsai G
    Psychopharmacology (Berl); 2004 Jun; 174(1):32-8. PubMed ID: 15205876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DARK Classics in Chemical Neuroscience: Phencyclidine (PCP).
    Bertron JL; Seto M; Lindsley CW
    ACS Chem Neurosci; 2018 Oct; 9(10):2459-2474. PubMed ID: 29953199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A half-century of participant observation in psychiatry. Part III: psychopharmacology.
    Rybakowski J
    Psychiatr Pol; 2020 Oct; 54(5):845-864. PubMed ID: 33529273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug treatments, from chlorpromazine to new molecules].
    Gaillard A; Poirier MF
    Soins Psychiatr; 2013; (286):25-9. PubMed ID: 23757890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors.
    Jardemark K; Marcus MM; Shahid M; Svensson TH
    Synapse; 2010 Nov; 64(11):870-4. PubMed ID: 20842721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential role of amino acids in pathogenesis of schizophrenia.
    Saleem S; Shaukat F; Gul A; Arooj M; Malik A
    Int J Health Sci (Qassim); 2017; 11(3):63-68. PubMed ID: 28936154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of group I metabotropic glutamate receptors in schizophrenia.
    Pietraszek M; Nagel J; Gravius A; Schäfer D; Danysz W
    Amino Acids; 2007 Feb; 32(2):173-8. PubMed ID: 16699816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review.
    Millan MJ
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):191-213. PubMed ID: 12769627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
    Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.
    Balu DT; Coyle JT
    Curr Opin Pharmacol; 2015 Feb; 20():109-15. PubMed ID: 25540902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine.
    Kargieman L; Santana N; Mengod G; Celada P; Artigas F
    Proc Natl Acad Sci U S A; 2007 Sep; 104(37):14843-8. PubMed ID: 17785415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.